文献速递瓣膜病与结构性心脏病心力衰竭与心肌病

酰基肉碱与重度主动脉瓣狭窄患者TAVR术后左室重构的关联

Association of Acylcarnitines With Left Ventricular Remodeling in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement.
PubMed 文献 · JAMA Cardiol · 2018-01-01

该单中心研究纳入44例接受经股动脉TAVR的症状性重度主动脉瓣狭窄患者,术前及术后24小时行液相色谱-质谱代谢组学分析。发现多种长链酰基肉碱独立关联左室质量指数,C18:2关联左室射血分数,且术后24小时酰基肉碱水平显著下降。

要点

  • 长链酰基肉碱独立关联左室质量指数,不受年龄、性别、糖尿病、肾功能和BNP影响
  • C18:2酰基肉碱与左室射血分数相关
  • TAVR术后24小时酰基肉碱水平显著下降

核心结论

  • 在症状性重度主动脉瓣狭窄接受TAVR的患者中,循环长链酰基肉碱水平独立关联不良左室重构指标,术后代谢紊乱减轻。
  • 这些新型生物标志物的临床适用性尚需进一步研究确定。

研究设计与样本

  • 单中心 tertiary care hospital 研究,纳入44例接受经股动脉TAVR的症状性重度主动脉瓣狭窄患者。
  • 术前及术后24小时采集血样,行液相色谱-质谱代谢组学分析,识别与左室重构指标相关的代谢物。

主要发现

  • 平均(SD)年龄81.9(8.5)岁,23例(52%)为女性;平均(SD)左室射血分数56.7%(18.2%),左室质量指数117.3(41.4)g/m2,相对室壁厚度0.53(0.14)。
  • 血代谢物水平未独立关联相对室壁厚度。
  • TAVR术后24小时内,循环C16下降30.2%(P=7.3×10-6),C18:1下降42.7%(P=3.7×10-8),C18:2下降37.3%(P=5.1×10-6),C18下降38.3%(P=3.4×10-5)。

临床怎么用

  • 长链酰基肉碱或可作为反映重度主动脉瓣狭窄患者左室不良重构的代谢标志物。
  • TAVR术后酰基肉碱水平快速下降,提示代谢紊乱可能部分逆转。

局限性

  • 单中心小样本研究(44例),结果需外部验证。
  • 仅评估术前及术后24小时代谢物变化,缺乏长期随访数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Clinical practice guidelines currently endorse a reliance on clinical symptoms of overt left ventricular (LV) failure to time aortic valve replacement for severe aortic stenosis; however, delayed aortic valve replacement can result in irreversible LV injury and adverse outcomes. Blood metabolomic signatures possess prognostic value in heart failure; this study assesses whether they are informative in aortic stenosis. OBJECTIVE: To evaluate the value of metabolomic signatures in reflecting the extent of maladaptive LV remodeling in patients with end-stage aortic stenosis undergoing transcatheter aortic valve replacement, and to assess whether this procedure reverses metabolomic aberrations. DESIGN, SETTING, AND PARTICIPANTS: This study of 44 patients with symptomatic severe aortic stenosis who underwent transfemoral transcatheter aortic valve replacement at a single-center tertiary care hospital. Liquid chromatography-mass spectrometry-based metabolomic profiling was performed on blood samples collected before and 24 hours after the procedure, and analyses were conducted to identify metabolites related to the measures of LV remodeling. MAIN OUTCOMES AND MEASURES: We evaluated LV ejection fraction, LV mass index, and relative wall thickness, as well as levels of the acylcarnitines C16, C18:1, C18:2, C18, C26, choline, and kynurenine. RESULTS: We enrolled 44 patients with severe aortic stenosis with a mean (SD) age of 81.9 (8.5) years, of whom 23 (52%) were women. The mean (SD) LV ejection fraction was 56.7% (18.2%), mean (SD) LV mass index was 117.3 (41.4) g/m2, and relative wall thickness was 0.53 (0.14). The mean β values of acylcarnitines C16, C18:1, C18:2, C18, and C26 were independently associated with LV mass index (C16: mean, 19.24; 95% CI, 5.48-33.01; P = .008; C18:1: mean, 26.18; 95% CI, 14.04-38.32; P < 1.0 × 10-4; C18:2: mean, 17.42; 95% CI, 3.40-31.43; P = .02; C18: mean, 25.25; 95% CI, 10.91-39.58; P = .001; C26: mean, 19.93; 95% CI, 4.41-35.45; P = .01), even after adjustments for age, sex, diabetes status, renal function, and B-type natriuretic peptide (BNP). Circulating levels of C18:2 acylcarnitine were associated with LV ejection fraction before and after multivariable adjustment (mean, -6.11; 95% CI, -10.88 to 1.34; P = .01). Blood metabolite levels did not independently relate to relative wall thickness. Within 24 hours of transcatheter aortic valve replacement, circulating levels of C16 decreased by 30.2% (P = 7.3 × 10-6), C18:1 by 42.7% (P = 3.7 × 10-8), C18:2 by 37.3% (P = 5.1 × 10-6), and C18 by 38.3% (P = 3.4 × 10-5). CONCLUSIONS AND RELEVANCE: In symptomatic patients with severe aortic stenosis undergoing transcatheter aortic valve replacement, circulating levels of long-chain acylcarnitines were independently associated with measures of maladaptive LV remodeling, and metabolic perturbations lessened after procedure completion. Further efforts are needed to determine the clinical applicability of these novel biomarkers.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Elmariah S, Farrell LA, Furman D, et al. Association of Acylcarnitines With Left Ventricular Remodeling in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement. JAMA Cardiol. 2018. PMID: 29299604. doi:10.1001/jamacardio.2017.4873

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。